Atomwise

Numerion Labs, formerly Atomwise, is an AI-native drug discovery company founded in 2012 that rebranded in 2025. It uses machine learning to search very large chemical spaces for novel, drug-like small molecules. The company describes its technology as an AI superplatform for exploring chemical space and identifying molecules not found by conventional screening. Numerion applies the platform to its own drug discovery programs, focused on immune and inflammatory diseases, and works with research partners through custom collaborations. Its team combines scientists and engineers working on small-molecule drug design.

• Machine-learning platform for small-molecule drug discovery
• Large-scale virtual exploration of chemical space
• In-house programs in immune and inflammatory diseases
• Custom research partnerships with pharma and biotech
• Rebranded from Atomwise to Numerion Labs in 2025